← FDA DRUG APPROVALS

FDA ANDA · ANDA210663

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

Sponsor: SANKALP LIFECARE

APPLICATION
ANDA210663
TYPE
ANDA
ORIGINAL APPROVAL
2019-06-11
LATEST ACTION
2019-06-11
ROUTE
ORAL
DOSAGE FORM
SYRUP
MARKETING STATUS
Discontinued

Products

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDEDiscontinued
HOMATROPINE METHYLBROMIDE 1.5MG/5ML, HYDROCODONE BITARTRATE 5MG/5ML · SYRUP · ORAL

Approval history

2019-06-11UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →